Triphenylarsine as an effective catalyst in a mechanistic investigation of trans- 1, 2-di (methoxycarbonyl)-6, 6-dimethyl-5, 7-dioxaspiro [2, 5] octane-4, 8-dione formation
ABSTRACT The kinetics and mechanism of the reaction between dimethyl acetylendicarboxylate (DMAD) and Meldrum's acid (MA) in the presence of triphenylarsine (TPA) as a catalyst were investigated in a methanol environment by the UV/vis spectrophotometry technique. In this work, the reaction followed second- order kinetics and the first and second steps of the reaction mechanism were recognized as the
MORIARTY, R. M.;VAID, R. K.;RAVIKUMAR, V. T.;HOPKINS, T. E.;FARID, P., TETRAHEDRON, 45,(1989) N, C. 1605-1610
作者:MORIARTY, R. M.、VAID, R. K.、RAVIKUMAR, V. T.、HOPKINS, T. E.、FARID, P.
DOI:——
日期:——
FOGLIO, M.;FRANCESCHI, G.;SCARAFILE, C.;ARCAMONE, F.
作者:FOGLIO, M.、FRANCESCHI, G.、SCARAFILE, C.、ARCAMONE, F.
DOI:——
日期:——
Novel compounds and their uses as thyroid hormone receptor agonists
申请人:Nanjing Ruijie Pharma Co., Ltd.
公开号:US20220162161A1
公开(公告)日:2022-05-26
A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto. (I), (Ia)